Adicet Bio Inc Ordinary Shares 1IJA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.22
- Day Range
- $1.38–1.38
- 52-Week Range
- $0.92–20.40
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $113.48 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 143
- Website
- https://www.adicetbio.com
Comparables
Valuation
|
Metric
|
1IJA
|
ANAB
|
RCUS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.47 | 14.33 | 2.17 |
Price/Sales | — | 29.08 | 5.51 |
Price/Cash Flow | — | — | — |
Price/Earnings
1IJA
ANAB
RCUS
Financial Strength
|
Metric
|
1IJA
|
ANAB
|
RCUS
|
|---|---|---|---|
Quick Ratio | 14.18 | 11.20 | 5.07 |
Current Ratio | 14.34 | 11.53 | 5.22 |
Interest Coverage | −21,431.00 | −8.08 | −135.00 |
Quick Ratio
1IJA
ANAB
RCUS
Profitability
|
Metric
|
1IJA
|
ANAB
|
RCUS
|
|---|---|---|---|
Return on Assets (Normalized) | −37.67% | −25.16% | −12.95% |
Return on Equity (Normalized) | −43.92% | −101.95% | −27.45% |
Return on Invested Capital (Normalized) | −44.18% | −87.63% | −33.04% |
Return on Assets
1IJA
ANAB
RCUS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yvzsnpjhj | Fmdc | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jjnnnth | Lnmyk | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ryykjdjrs | Mfvbyxd | $108.2 Bil | |
MRNA
| Moderna Inc | Hxhbmlsrv | Skbds | $50.9 Bil | |
ARGX
| argenx SE ADR | Ntjwqmld | Hdwsw | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Xhrcyxjf | Tyzfn | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tkrqrfxws | Sygzvfx | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wgcbqzfyc | Hbwbr | $14.6 Bil | |
INCY
| Incyte Corp | Lwldskkf | Slnjsn | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mrmsqtjsm | Npjbdr | $12.3 Bil |